A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

Inclusion criteria: * Healthy Caucasian male subjects or healthy Caucasian female subjects of non-childbearing potential * Aged between 18-55 years * Non-smokers * Normal spirometry (FEV1 = 80% of predicted, FEV1/FVC = 70%) * A signed and dated written informed consent is obtained from the subject * The subject is capable of giving informed consent * Available to complete the study * Subject has a BMI within the range 18.0-30.0kg/m2 inclusive Exclusion criteria: * Any clinically important abnormality identified at the screening medical assessment * A history of breathing problems * A mean QTc(B) value at screening \>450msec, the QTc(B) of all 3 screening ECGs are not within 10% of the mean, or an ECG that is not suitable for QT measurements * A history of elevated resting blood pressure or a mean blood pressure equal to or higher than 140/90 mmHg at screening * A mean heart rate outside the range 40-90 bpm at screening * History of use of tobacco products within 6 months of screening, or positive urine cotinine at screening * Subjects with a 2D6 poor metabolizer genotype (Caucasian) * The subject has donated a unit (400ml) of blood within 60 days of screening, or, intends to donate during the study * The subject is currently taking regular (or course of) medication, whether prescribed or not * The subject has taken prescription medications within the past 2 weeks prior to dosing or OTC medications within 48 hours prior to dosing * The subject has participated in a study with a new molecular entity or any other trial within a period of 3 months prior to dosing * The subject has tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV * The subject has a positive pre-study drug screen * The subject has a positive pre-study alcohol screen * The subject has a suspected history of alcohol abuse within the six months previous to the screening visit * The subject is unable to use the DISKUS * The subject has a known allergy or hypersensitivity to ipratropium bromide, atropine and any of its derivatives * The subject has a known allergy or hypersensitivity to milk protein or the excipient lactose monohydrate * Subjects who might have prostatic hypertrophy, bladder outlet obstruction, or narrow angle glaucoma